Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients

Background: The primary non-response (PNR) rate of infliximab (IFX) varies from 20 to 46% for the treatment of Crohn’s disease (CD). Detected PNR reduces the improper use of specific treatments. To date, there is hardly any knowledge regarding early markers of PNR. The aim of this study was to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yueying, Li, Hanyang, Feng, Qi, Shen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112246/
https://www.ncbi.nlm.nih.gov/pubmed/33986682
http://dx.doi.org/10.3389/fphar.2021.654985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112246/
https://www.ncbi.nlm.nih.gov/pubmed/33986682
http://dx.doi.org/10.3389/fphar.2021.654985

Ejemplares similares